You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMesalazine
Accession NumberDB00244  (APRD01098)
TypeSmall Molecule
GroupsApproved
Description

An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Structure
Thumb
Synonyms
3-carboxy-4-hydroxyaniline
5-aminosalicylic acid
5-ASA
Asacol
Asacolitin
Canasa
Claversal
Fisalamine
Iialda
Lixacol
m-Aminosalicylic acid
Mesalamine
Mesalazina
Mesalazine
Mesalazinum
Mesasal
P-Aminosalicylsaeure
Pentasa
Rowasa
Salofalk
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
5-asatablet (enteric-coated)400 mgoralSanis Health Inc2010-11-022012-08-03Canada
Aprisocapsule, extended release375 mg/1oralPhysicians Total Care, Inc.2010-08-18Not applicableUs
Aprisocapsule, extended release375 mg/1oralSalix Pharmaceuticals, Inc.2008-10-31Not applicableUs
Asacoltablet, delayed release400 mg/1oralKAISER FOUNDATION HOSPITALS2012-02-23Not applicableUs
Asacoltablet (enteric-coated)400 mgoralWarner Chilcott Canada Co1993-12-31Not applicableCanada
Asacoltablet, delayed release400 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Asacoltablet400 mg/1oralREMEDYREPACK INC.2011-08-17Not applicableUs
Asacoltablet, delayed release400 mg/1oralCardinal Health1992-04-01Not applicableUs
Asacoltablet, delayed release400 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Asacoltablet, delayed release400 mg/1oralCardinal Health1992-04-01Not applicableUs
Asacoltablet, delayed release400 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
Asacoltablet, delayed release400 mg/1oralWarner Chilcott (US), LLC1992-04-01Not applicableUs
Asacoltablet, delayed release400 mg/1oralREMEDYREPACK INC.2012-03-30Not applicableUs
Asacoltablet, delayed release400 mg/1oralAmerican Health Packaging2012-01-232015-12-29Us
Asacoltablet, delayed release400 mg/1oralREMEDYREPACK INC.2011-03-09Not applicableUs
Asacol 800tablet (delayed-release)800 mgoralWarner Chilcott Canada Co2005-06-13Not applicableCanada
Asacol Hdtablet, delayed release800 mg/1oralWarner Chilcott (US), LLC2008-05-28Not applicableUs
Canasasuppository1000 mg/1rectalAptalis Pharma Us Inc2001-01-05Not applicableUs
Canasasuppository1000 mg/1rectalPhysicians Total Care, Inc.2010-08-18Not applicableUs
Delzicolcapsule, delayed release400 mg/1oralCarilion Materials Management2013-03-01Not applicableUs
Delzicolcapsule, delayed release400 mg/1oralWarner Chilcott (US), LLC2013-03-01Not applicableUs
Delzicolcapsule, delayed release400 mg/1oralWarner Chilcott (US), LLC2016-03-312016-04-13Us
Lialdatablet, delayed release1.2 g/1oralShire US Manufacturing Inc.2007-01-16Not applicableUs
Lialdatablet, delayed release1.2 g/1oralKAISER FOUNDATION HOSPITALS2013-12-06Not applicableUs
Mesalaminesuspension4 g/60mLrectalFranklin Pharmaceutical LLC2010-04-01Not applicableUs
Mesalaminecapsule500 mg/1oralPrasco Laboratories2004-07-08Not applicableUs
Mesalaminecapsule250 mg/1oralPrasco Laboratories1993-05-10Not applicableUs
Mesasaltablet (enteric-coated)500 mgoralGlaxosmithkline Inc1992-12-31Not applicableCanada
Mezavanttablet (delayed and extended release)1.2 goralShire Pharma Canada Ulc2007-07-27Not applicableCanada
Ntp-5-aminosalicylic Acidtablet (enteric-coated)400 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-5 Asatablet (enteric-coated)400 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pentasacapsule250 mg/1oralShire US Manufacturing Inc.1993-05-10Not applicableUs
Pentasatablet (extended-release)1.00 goralFerring Inc2013-03-12Not applicableCanada
Pentasacapsule250 mg/1oralAvera Mc Kennan Hospital2015-04-27Not applicableUs
Pentasacapsule500 mg/1oralREMEDYREPACK INC.2011-10-04Not applicableUs
Pentasacapsule250 mg/1oralCardinal Health1993-05-10Not applicableUs
Pentasacapsule250 mg/1oralCarilion Materials Management1993-05-10Not applicableUs
Pentasacapsule500 mg/1oralShire US Manufacturing Inc.2004-07-08Not applicableUs
Pentasa Enema 1g/100mlenema; liquid1 grectalFerring Inc1995-12-31Not applicableCanada
Pentasa Enema 2g/100mlenema; liquid2 grectalFerring Inc1995-12-312004-08-05Canada
Pentasa Enema 4g/100mlenema; liquid4 grectalFerring Inc1995-12-31Not applicableCanada
Pentasa Extended-release Tablets 250mgtablet (extended-release)250 mgoralFerring Inc1995-12-312004-08-05Canada
Pentasa Extended-release Tablets 500mgtablet (extended-release)500 mgoralFerring Inc1994-12-31Not applicableCanada
Pentasa Suppository - 1gsuppository1 grectalFerring Inc1995-12-31Not applicableCanada
Rowasaenema4 g/60mLrectalAlaven Pharmaceutical LLC1988-01-31Not applicableUs
Rowasasuspension4 g/60mLrectalMEDA Pharmaceuticals2016-03-29Not applicableUs
Salofalksuppository1000 mgrectalAptalis Pharma Canada Inc2000-06-01Not applicableCanada
Salofalktablet (enteric-coated)500 mgoralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Salofalksuppository500 mgrectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Salofalksuspension2 grectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Salofalksuspension4 grectalAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Salofalk (r) 5-asa Enteric Coated Tab- 250mgtablet (enteric-coated)250 mgoralAxcan Pharma Inc1995-12-311998-08-03Canada
Salofalk (r) 5-asa Suppositories - 250mgsuppository250 mgrectalAxcan Pharma Inc1995-12-312006-09-12Canada
Sf Rowasasuspension4 g/60mLrectalAlaven Pharmaceutical LLC2009-09-01Not applicableUs
Sfrowasa Sulfite-free Formulationsuspension4 g/60mLrectalMEDA Pharmaceuticals2016-03-29Not applicableUs
Teva-5 Asatablet (enteric-coated)400 mgoralTeva Canada Limited1995-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mesalamineenema4 g/60mLrectalGAVIS Pharmaceuticals, LLC2009-12-16Not applicableUs
MesalaminekitPerrigo New York Inc2009-09-01Not applicableUs
Mesalamineenema4 g/60mLrectalPerrigo New York Inc2007-10-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AsacolitinNot Available
ClaversalNot Available
FisalamineNot Available
LixacolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4Q81I59GXC
CAS number89-57-6
WeightAverage: 153.1354
Monoisotopic: 153.042593095
Chemical FormulaC7H7NO3
InChI KeyInChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
IUPAC Name
5-amino-2-hydroxybenzoic acid
SMILES
NC1=CC(C(O)=O)=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aminophenol
  • Phenol
  • Aniline
  • Primary aromatic amine
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of active ulcerative proctitis.
PharmacodynamicsMesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.
Mechanism of actionAlthough the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
Related Articles
Absorption20 to 30% absorbed following oral administration. 10 to 35% absorbed from the colon (rectal suppository) - extent of absorption is determined by the length of time the drug is retained in the colon.
Volume of distributionNot Available
Protein bindingAbout 80% of N-Ac-5-ASA is bound to plasma proteins, whereas 40% of mesalamine is protein bound.
Metabolism

Rapidly and extensively metabolized, mainly to N-acetyl-5-ASA (Ac-5-ASA) in the intestinal mucosal wall and the liver. Ac-5-ASA is further acetylated (deactivated) in at least 2 sites, the colonic epithelium and the liver.

SubstrateEnzymesProduct
Mesalazine
Not Available
N-acetyl-5-ASA (Ac-5-ASA)Details
Route of eliminationApproximately 28% of the mesalamine in Asacol tablets is absorbed after oral ingestion, leaving the remainder available for topical action and excretion in the feces. It is excreted mainly by the kidney as N-acetyl-5-aminosalicylic acid.
Half lifeThe mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.
ClearanceNot Available
ToxicityOral, mouse: LD50 = 3370 mg/kg; Oral, rat: LD50 = 2800 mg/kg; Skin, rabbit: LD50 = >5 gm/kg. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalazine absorption from the colon is limited.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9471
Blood Brain Barrier-0.6168
Caco-2 permeable-0.8829
P-glycoprotein substrateNon-substrate0.8186
P-glycoprotein inhibitor INon-inhibitor0.985
P-glycoprotein inhibitor IINon-inhibitor0.9912
Renal organic cation transporterNon-inhibitor0.9314
CYP450 2C9 substrateNon-substrate0.8284
CYP450 2D6 substrateNon-substrate0.8331
CYP450 3A4 substrateNon-substrate0.7636
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8712
CYP450 2D6 inhibitorNon-inhibitor0.9744
CYP450 2C19 inhibitorInhibitor0.6752
CYP450 3A4 inhibitorNon-inhibitor0.6628
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9023
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7922
BiodegradationReady biodegradable0.6197
Rat acute toxicity1.7065 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9759
hERG inhibition (predictor II)Non-inhibitor0.9715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Salix pharmaceuticals inc
  • Shire development inc
  • Perrigo israel pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Alaven pharmaceutical llc
  • Axcan pharma us inc
  • Warner chilcott pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral375 mg/1
Tabletoral400 mg/1
Tablet (enteric-coated)oral400 mg
Tablet, delayed releaseoral400 mg/1
Tablet (delayed-release)oral800 mg
Tablet, delayed releaseoral800 mg/1
Suppositoryrectal1000 mg/1
Capsule, delayed releaseoral400 mg/1
Tablet, delayed releaseoral1.2 g/1
Enemarectal4 g/60mL
Kit
Suspensionrectal4 g/60mL
Tablet (enteric-coated)oral500 mg
Tablet (delayed and extended release)oral1.2 g
Capsuleoral250 mg/1
Capsuleoral500 mg/1
Tablet (extended-release)oral1.00 g
Enema; liquidrectal1 g
Enema; liquidrectal2 g
Enema; liquidrectal4 g
Tablet (extended-release)oral250 mg
Tablet (extended-release)oral500 mg
Suppositoryrectal1 g
Suppositoryrectal1000 mg
Suppositoryrectal500 mg
Suspensionrectal2 g
Suspensionrectal4 g
Tablet (enteric-coated)oral250 mg
Suppositoryrectal250 mg
Prices
Unit descriptionCostUnit
Canasa 30 1000 mg Suppository Box488.32USD box
Canasa 1000 mg suppository13.88USD suppository
Salofalk (4 g/60 g) 4 g/enm Enema6.73USD enema
Canasa 500 mg suppository6.24USD suppository
Pentasa (4 g/100 Ml) 4 g/enm Enema5.02USD enema
Pentasa (1 g/100Ml) 1 g/enm Enema4.17USD enema
Salofalk (2 g/60 g) 2 g/enm Enema3.96USD enema
Asacol hd dr 800 mg tablet3.88USD tablet
Pentasa 500 mg capsule2.66USD capsule
Asacol 400 mg Enteric Coated Tabs2.22USD tab
Asacol ec 400 mg tablet1.94USD tablet
Salofalk 1000 mg Suppository1.81USD suppository
Pentasa 1 g Suppository1.8USD suppository
Salofalk 500 mg Suppository1.23USD suppository
Asacol 800 800 mg Enteric-Coated Tablet1.14USD tablet
Pentasa 250 mg capsule1.07USD capsule
Mesasal 500 mg Enteric-Coated Tablet0.69USD tablet
Pentasa 500 mg Sustained-Release Tablet0.63USD tablet
Asacol 400 mg Enteric-Coated Tablet0.59USD tablet
Salofalk 500 mg Enteric-Coated Tablet0.56USD tablet
Novo-5 Asa 400 mg Enteric-Coated Tablet0.42USD tablet
Rowasa 4 gm/60 ml enema0.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2111697 No2002-08-202012-06-16Canada
CA2444814 No2009-06-092021-10-24Canada
US5541170 No1993-07-302013-07-30Us
US6551620 No1998-04-202018-04-20Us
US6649180 No2000-04-132020-04-13Us
US6773720 No2000-06-082020-06-08Us
US6893662 No2001-11-152021-11-15Us
US7645801 No2007-07-242027-07-24Us
US8217083 No2008-06-062028-06-06Us
US8337886 No1998-04-202018-04-20Us
US8436051 No2008-06-062028-06-06Us
US8496965 No1998-04-202018-04-20Us
US8580302 No2001-11-152021-11-15Us
US8865688 No2010-05-012030-05-01Us
US8911778 No1998-04-202018-04-20Us
US8940328 No1998-04-202018-04-20Us
US8956647 No1998-04-202018-04-20Us
US9089492 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point283 °CPhysProp
water solubility0.84 g/L at 20°CNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.2 mg/mLALOGPS
logP0.75ALOGPS
logP-0.29ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.02ChemAxon
pKa (Strongest Basic)5.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity40 m3·mol-1ChemAxon
Polarizability14.26 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.48 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., “Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract.” U.S. Patent US4298595, issued January, 1975.

US4298595
General References
  1. Link [Link]
External Links
ATC CodesA07EC02
AHFS Codes
  • 56:36.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (67.7 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Mesalazine is combined with 4-Androstenedione.
AbciximabMesalazine may increase the anticoagulant activities of Abciximab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Mesalazine.
AcarboseMesalazine may increase the hypoglycemic activities of Acarbose.
AcebutololMesalazine may decrease the antihypertensive activities of Acebutolol.
AceclofenacAceclofenac may increase the nephrotoxic activities of Mesalazine.
AceclofenacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Aceclofenac.
AcenocoumarolMesalazine may increase the anticoagulant activities of Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Mesalazine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acetylsalicylic acid.
AdapaleneAdapalene may increase the nephrotoxic activities of Mesalazine.
AdapaleneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Adapalene.
AlbiglutideMesalazine may increase the hypoglycemic activities of Albiglutide.
AlclometasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alclometasone.
AldosteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Aldosterone.
Alendronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.
AliskirenMesalazine may decrease the antihypertensive activities of Aliskiren.
AlogliptinMesalazine may increase the hypoglycemic activities of Alogliptin.
AlprenololMesalazine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mesalazine.
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Mesalazine.
AlteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alteplase.
Aluminum hydroxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.
Aluminum phosphateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum phosphate.
ALX-0081The risk or severity of adverse effects can be increased when Mesalazine is combined with ALX-0081.
AmcinonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Amcinonide.
AmikacinMesalazine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMesalazine may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Mesalazine.
Ammonium chlorideThe serum concentration of Mesalazine can be increased when it is combined with Ammonium chloride.
AnagrelideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Anagrelide.
AncrodMesalazine may increase the anticoagulant activities of Ancrod.
AnistreplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Anistreplase.
AntipyrineAntipyrine may increase the nephrotoxic activities of Mesalazine.
AntipyrineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Antipyrine.
Antithrombin III humanMesalazine may increase the anticoagulant activities of Antithrombin III human.
ApixabanMesalazine may increase the anticoagulant activities of Apixaban.
ApremilastApremilast may increase the nephrotoxic activities of Mesalazine.
ApremilastThe risk or severity of adverse effects can be increased when Mesalazine is combined with Apremilast.
ArdeparinMesalazine may increase the anticoagulant activities of Ardeparin.
ArgatrobanMesalazine may increase the anticoagulant activities of Argatroban.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Mesalazine.
ArotinololMesalazine may decrease the antihypertensive activities of Arotinolol.
AsenapineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine.
AstaxanthinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Astaxanthin.
AtenololMesalazine may decrease the antihypertensive activities of Atenolol.
AzapropazoneAzapropazone may increase the nephrotoxic activities of Mesalazine.
AzapropazoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Azapropazone.
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Mesalazine.
AzelastineAzelastine may increase the nephrotoxic activities of Mesalazine.
AzelastineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mesalazine.
BalsalazideMesalazine may increase the nephrotoxic activities of Balsalazide.
BatroxobinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Batroxobin.
BecaplerminMesalazine may increase the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone dipropionate.
BefunololMesalazine may decrease the antihypertensive activities of Befunolol.
BemiparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mesalazine.
BenazeprilMesalazine may decrease the antihypertensive activities of Benazepril.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Mesalazine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Benoxaprofen.
BeraprostThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beraprost.
BetamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Betamethasone.
BetaxololMesalazine may decrease the antihypertensive activities of Betaxolol.
BevantololMesalazine may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mesalazine.
Bismuth SubcitrateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Bismuth Subcitrate.
BisoprololMesalazine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMesalazine may increase the anticoagulant activities of Bivalirudin.
BopindololMesalazine may decrease the antihypertensive activities of Bopindolol.
BromfenacBromfenac may increase the nephrotoxic activities of Mesalazine.
BromfenacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bromfenac.
BromocriptineMesalazine may increase the hypoglycemic activities of Bromocriptine.
BudesonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.
BufuralolMesalazine may decrease the antihypertensive activities of Bufuralol.
BumetanideMesalazine may decrease the diuretic activities of Bumetanide.
BupranololMesalazine may decrease the antihypertensive activities of Bupranolol.
Calcium carbonateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Calcium carbonate.
CanagliflozinMesalazine may increase the hypoglycemic activities of Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mesalazine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mesalazine.
CandoxatrilMesalazine may decrease the antihypertensive activities of Candoxatril.
CangrelorThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cangrelor.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mesalazine.
CaptoprilMesalazine may decrease the antihypertensive activities of Captopril.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mesalazine.
CarprofenCarprofen may increase the nephrotoxic activities of Mesalazine.
CarprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Carprofen.
CarteololMesalazine may decrease the antihypertensive activities of Carteolol.
CarvedilolMesalazine may decrease the antihypertensive activities of Carvedilol.
CastanospermineCastanospermine may increase the nephrotoxic activities of Mesalazine.
CastanospermineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Castanospermine.
CelecoxibCelecoxib may increase the nephrotoxic activities of Mesalazine.
CelecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Celecoxib.
CeliprololMesalazine may decrease the antihypertensive activities of Celiprolol.
CertoparinMesalazine may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the nephrotoxic activities of Mesalazine.
ChloroquineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.
ChlorpropamideMesalazine may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.
CholestyramineCholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ciclesonide.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mesalazine.
CilazaprilMesalazine may decrease the antihypertensive activities of Cilazapril.
CilostazolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cilostazol.
CimetidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.
Citric AcidMesalazine may increase the anticoagulant activities of Citric Acid.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasol propionate.
ClocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone.
ClodronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clodronate.
ClonixinClonixin may increase the nephrotoxic activities of Mesalazine.
ClonixinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clonixin.
ClopidogrelThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mesalazine.
ColesevelamColesevelam can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cortisone acetate.
CyclosporineMesalazine may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may increase the nephrotoxic activities of Mesalazine.
D-LimoneneThe risk or severity of adverse effects can be increased when Mesalazine is combined with D-Limonene.
Dabigatran etexilateMesalazine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinMesalazine may increase the anticoagulant activities of Dalteparin.
DanaparoidMesalazine may increase the anticoagulant activities of Danaparoid.
DapagliflozinMesalazine may increase the hypoglycemic activities of Dapagliflozin.
DaunorubicinMesalazine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Mesalazine is combined with Deferasirox.
DefibrotideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Defibrotide.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dehydroepiandrosterone.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Mesalazine is combined with dehydroepiandrosterone sulfate.
DesirudinMesalazine may increase the anticoagulant activities of Desirudin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.
DesmopressinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.
DesmoteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desmoteplase.
DesoximetasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoximetasone.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Desoxycorticosterone acetate.
DexamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone isonicotinate.
DexketoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexketoprofen.
DextranMesalazine may increase the anticoagulant activities of Dextran.
Dextran 40Mesalazine may increase the anticoagulant activities of Dextran 40.
Dextran 70Mesalazine may increase the anticoagulant activities of Dextran 70.
Dextran 75Mesalazine may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide.
DicoumarolMesalazine may increase the anticoagulant activities of Dicoumarol.
DiflorasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diflorasone.
DiflunisalDiflunisal may increase the nephrotoxic activities of Mesalazine.
DiflunisalThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diflunisal.
DifluocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluocortolone.
DifluprednateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluprednate.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mesalazine.
DihydrostreptomycinMesalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mesalazine.
DipyridamoleThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dipyridamole.
DisopyramideMesalazine may increase the hypoglycemic activities of Disopyramide.
DitazoleThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ditazole.
DoxepinThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.
DoxorubicinMesalazine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneMesalazine may increase the hyperkalemic activities of Drospirenone.
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Mesalazine is combined with Drotrecogin alfa.
DroxicamDroxicam may increase the nephrotoxic activities of Mesalazine.
DroxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Droxicam.
DulaglutideMesalazine may increase the hypoglycemic activities of Dulaglutide.
Edetic AcidMesalazine may increase the anticoagulant activities of Edetic Acid.
EdoxabanMesalazine may increase the anticoagulant activities of Edoxaban.
EmpagliflozinMesalazine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mesalazine.
EnalaprilMesalazine may decrease the antihypertensive activities of Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mesalazine.
EnalaprilatMesalazine may decrease the antihypertensive activities of Enalaprilat.
EnoxaparinMesalazine may increase the anticoagulant activities of Enoxaparin.
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Mesalazine.
EpirizoleEpirizole may increase the nephrotoxic activities of Mesalazine.
EpirizoleThe risk or severity of adverse effects can be increased when Mesalazine is combined with Epirizole.
EpirubicinMesalazine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMesalazine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mesalazine.
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Mesalazine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mesalazine.
EptifibatideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Eptifibatide.
EquileninThe risk or severity of adverse effects can be increased when Mesalazine is combined with Equilenin.
EquilinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Equilin.
EsmololMesalazine may decrease the antihypertensive activities of Esmolol.
EsomeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Esomeprazole.
EstroneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone.
Etacrynic acidMesalazine may decrease the diuretic activities of Etacrynic acid.
EtanerceptEtanercept may increase the nephrotoxic activities of Mesalazine.
EtanerceptThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etanercept.
EthoxzolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ethoxzolamide.
Ethyl biscoumacetateMesalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etidronic acid.
EtodolacEtodolac may increase the nephrotoxic activities of Mesalazine.
EtodolacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etodolac.
EtofenamateEtofenamate may increase the nephrotoxic activities of Mesalazine.
EtofenamateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etofenamate.
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Mesalazine.
EtoricoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etoricoxib.
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Mesalazine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Mesalazine is combined with Evening primrose oil.
ExenatideMesalazine may increase the hypoglycemic activities of Exenatide.
exisulindexisulind may increase the nephrotoxic activities of Mesalazine.
exisulindThe risk or severity of adverse effects can be increased when Mesalazine is combined with exisulind.
FamotidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Famotidine.
FenbufenFenbufen may increase the nephrotoxic activities of Mesalazine.
FenbufenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fenbufen.
FenoprofenFenoprofen may increase the nephrotoxic activities of Mesalazine.
FenoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fenoprofen.
FibrinolysinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fibrinolysin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mesalazine.
FludrocortisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fludrocortisone.
FlumethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flumethasone.
FlunisolideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flunisolide.
FlunixinFlunixin may increase the nephrotoxic activities of Mesalazine.
FlunixinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flunixin.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinolone Acetonide.
FluocinonideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinonide.
FluocortoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocortolone.
FluorometholoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluorometholone.
FluprednideneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluprednidene.
FluprednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluprednisolone.
FlurandrenolideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurandrenolide.
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Mesalazine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flurbiprofen.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone furoate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone Propionate.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mesalazine.
Fondaparinux sodiumMesalazine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mesalazine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mesalazine.
FosinoprilMesalazine may decrease the antihypertensive activities of Fosinopril.
FramycetinMesalazine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMesalazine may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mesalazine.
GentamicinMesalazine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Mesalazine.
GliclazideMesalazine may increase the hypoglycemic activities of Gliclazide.
GlimepirideMesalazine may increase the hypoglycemic activities of Glimepiride.
GlipizideMesalazine may increase the hypoglycemic activities of Glipizide.
GlyburideMesalazine may increase the hypoglycemic activities of Glyburide.
HaloperidolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.
HeparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Heparin.
HirulogMesalazine may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the nephrotoxic activities of Mesalazine.
HMPL-004The risk or severity of adverse effects can be increased when Mesalazine is combined with HMPL-004.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mesalazine.
HydralazineMesalazine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.
HydrocortisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.
Hygromycin BMesalazine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Mesalazine.
IbuprofenIbuprofen may increase the nephrotoxic activities of Mesalazine.
IbuprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibuprofen.
IbuproxamIbuproxam may increase the nephrotoxic activities of Mesalazine.
IbuproxamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibuproxam.
IcatibantIcatibant may increase the nephrotoxic activities of Mesalazine.
IcatibantThe risk or severity of adverse effects can be increased when Mesalazine is combined with Icatibant.
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Mesalazine.
IdarubicinMesalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Mesalazine.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mesalazine.
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.
IndenololMesalazine may decrease the antihypertensive activities of Indenolol.
IndomethacinIndomethacin may increase the nephrotoxic activities of Mesalazine.
IndomethacinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Indomethacin.
IndoprofenIndoprofen may increase the nephrotoxic activities of Mesalazine.
IndoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Indoprofen.
Insulin AspartMesalazine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirMesalazine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineMesalazine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineMesalazine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanMesalazine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproMesalazine may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.
IsoxicamIsoxicam may increase the nephrotoxic activities of Mesalazine.
IsoxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Isoxicam.
KanamycinMesalazine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may increase the nephrotoxic activities of Mesalazine.
KebuzoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Kebuzone.
KetoprofenKetoprofen may increase the nephrotoxic activities of Mesalazine.
KetoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.
LabetalolMesalazine may decrease the antihypertensive activities of Labetalol.
LanreotideMesalazine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole.
LeflunomideLeflunomide may increase the nephrotoxic activities of Mesalazine.
LeflunomideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Leflunomide.
LepirudinMesalazine may increase the anticoagulant activities of Lepirudin.
LevobunololMesalazine may decrease the antihypertensive activities of Levobunolol.
LiraglutideMesalazine may increase the hypoglycemic activities of Liraglutide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mesalazine.
LisinoprilMesalazine may decrease the antihypertensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Mesalazine.
LornoxicamLornoxicam may increase the nephrotoxic activities of Mesalazine.
LornoxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Mesalazine.
LoxoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mesalazine.
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Mesalazine.
LumiracoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Lumiracoxib.
MagaldrateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magaldrate.
Magnesium carbonateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium carbonate.
Magnesium hydroxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium hydroxide.
Magnesium oxideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Mesalazine.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Magnesium salicylate.
Magnesium TrisilicateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium Trisilicate.
MasoprocolMasoprocol may increase the nephrotoxic activities of Mesalazine.
MasoprocolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Masoprocol.
MecaserminMesalazine may increase the hypoglycemic activities of Mecasermin.
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Mesalazine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Meclofenamic acid.
MedrysoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Medrysone.
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Mesalazine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mefenamic acid.
MelengestrolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Melengestrol.
MeloxicamMeloxicam may increase the nephrotoxic activities of Mesalazine.
MeloxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Meloxicam.
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Mesalazine.
MetamizoleMetamizole may increase the nephrotoxic activities of Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Mesalazine is combined with Metamizole.
MetforminMesalazine may increase the hypoglycemic activities of Metformin.
MethanthelineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methazolamide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mesalazine.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone.
MetiamideThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Metiamide.
MetipranololMesalazine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.
MetoprololMesalazine may decrease the antihypertensive activities of Metoprolol.
MetrizamideMesalazine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneMesalazine may increase the hypoglycemic activities of Mifepristone.
MiglitolMesalazine may increase the hypoglycemic activities of Miglitol.
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Mesalazine.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mesalazine.
MoexiprilMesalazine may decrease the antihypertensive activities of Moexipril.
MometasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mesalazine.
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Mesalazine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mycophenolate mofetil.
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Mesalazine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mycophenolic acid.
NabumetoneNabumetone may increase the nephrotoxic activities of Mesalazine.
NabumetoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nabumetone.
NadololMesalazine may decrease the antihypertensive activities of Nadolol.
NadroparinMesalazine may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the nephrotoxic activities of Mesalazine.
NaftifineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Naftifine.
NaproxenNaproxen may increase the nephrotoxic activities of Mesalazine.
NaproxenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Naproxen.
NateglinideMesalazine may increase the hypoglycemic activities of Nateglinide.
NCX 4016NCX 4016 may increase the nephrotoxic activities of Mesalazine.
NCX 4016The risk or severity of adverse effects can be increased when Mesalazine is combined with NCX 4016.
NeomycinMesalazine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may increase the nephrotoxic activities of Mesalazine.
NepafenacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nepafenac.
NetilmicinMesalazine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Mesalazine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Niflumic Acid.
NimesulideNimesulide may increase the nephrotoxic activities of Mesalazine.
NimesulideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nimesulide.
NizatidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Nizatidine.
OctreotideMesalazine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mesalazine.
OlopatadineOlopatadine may increase the nephrotoxic activities of Mesalazine.
OlopatadineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Olopatadine.
OlsalazineMesalazine may increase the nephrotoxic activities of Olsalazine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mesalazine.
OmapatrilatMesalazine may decrease the antihypertensive activities of Omapatrilat.
OmeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Omeprazole.
OrgoteinOrgotein may increase the nephrotoxic activities of Mesalazine.
OrgoteinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Orgotein.
OtamixabanMesalazine may increase the anticoagulant activities of Otamixaban.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Mesalazine.
OxaprozinOxaprozin may increase the nephrotoxic activities of Mesalazine.
OxaprozinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oxaprozin.
OxprenololMesalazine may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Mesalazine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pamidronate.
PantoprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Pantoprazole.
ParamethasoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Paramethasone.
ParecoxibParecoxib may increase the nephrotoxic activities of Mesalazine.
ParecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parecoxib.
ParnaparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parnaparin.
ParomomycinMesalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PasireotideMesalazine may increase the hypoglycemic activities of Pasireotide.
PenbutololMesalazine may decrease the antihypertensive activities of Penbutolol.
PentamidineMesalazine may increase the hypoglycemic activities of Pentamidine.
Pentosan PolysulfateMesalazine may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Mesalazine.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mesalazine.
PerindoprilMesalazine may decrease the antihypertensive activities of Perindopril.
PhenindioneMesalazine may increase the anticoagulant activities of Phenindione.
PhenprocoumonMesalazine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Mesalazine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Phenylbutazone.
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Mesalazine.
PimecrolimusThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pimecrolimus.
PindololMesalazine may decrease the antihypertensive activities of Pindolol.
PioglitazoneMesalazine may increase the hypoglycemic activities of Pioglitazone.
PiretanideMesalazine may decrease the diuretic activities of Piretanide.
PirfenidonePirfenidone may increase the nephrotoxic activities of Mesalazine.
PirfenidoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pirfenidone.
PiroxicamPiroxicam may increase the nephrotoxic activities of Mesalazine.
PiroxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Piroxicam.
PlasminThe risk or severity of adverse effects can be increased when Mesalazine is combined with Plasmin.
PlicamycinMesalazine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mesalazine.
PractololMesalazine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mesalazine.
PramlintideMesalazine may increase the hypoglycemic activities of Pramlintide.
PrasugrelThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prasugrel.
PrednicarbateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednicarbate.
PrednisoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.
PrednisoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisone.
PregnenoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pregnenolone.
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Mesalazine.
ProbenecidThe serum concentration of Mesalazine can be increased when it is combined with Probenecid.
PropacetamolPropacetamol may increase the nephrotoxic activities of Mesalazine.
PropacetamolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Propacetamol.
PropranololMesalazine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mesalazine.
Protein CMesalazine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMesalazine may increase the anticoagulant activities of Protocatechualdehyde.
PTC299PTC299 may increase the nephrotoxic activities of Mesalazine.
PTC299The risk or severity of adverse effects can be increased when Mesalazine is combined with PTC299.
PuromycinMesalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mesalazine.
QuinaprilMesalazine may decrease the antihypertensive activities of Quinapril.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.
QuinineMesalazine may increase the hypoglycemic activities of Quinine.
RabeprazoleThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Rabeprazole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mesalazine.
RamiprilMesalazine may decrease the antihypertensive activities of Ramipril.
RanitidineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Ranitidine.
RepaglinideMesalazine may increase the hypoglycemic activities of Repaglinide.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mesalazine.
RescinnamineMesalazine may decrease the antihypertensive activities of Rescinnamine.
ResveratrolResveratrol may increase the nephrotoxic activities of Mesalazine.
ResveratrolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Resveratrol.
ReteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Reteplase.
ReviparinMesalazine may increase the anticoagulant activities of Reviparin.
RibostamycinMesalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Mesalazine.
RimexoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rimexolone.
RisedronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Risedronate.
RivaroxabanMesalazine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the nephrotoxic activities of Mesalazine.
RofecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rofecoxib.
RosiglitazoneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rosiglitazone.
Roxatidine acetateThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Roxatidine acetate.
SalicylamideSalicylamide may increase the nephrotoxic activities of Mesalazine.
SalicylamideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salicylamide.
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Mesalazine.
Salicylic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salicylic acid.
SalsalateSalsalate may increase the nephrotoxic activities of Mesalazine.
SalsalateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mesalazine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mesalazine.
SaxagliptinMesalazine may increase the hypoglycemic activities of Saxagliptin.
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Mesalazine.
SelexipagThe risk or severity of adverse effects can be increased when Mesalazine is combined with Selexipag.
SeratrodastSeratrodast may increase the nephrotoxic activities of Mesalazine.
SeratrodastThe risk or severity of adverse effects can be increased when Mesalazine is combined with Seratrodast.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesalazine.
SitagliptinMesalazine may increase the hypoglycemic activities of Sitagliptin.
SotalolMesalazine may decrease the antihypertensive activities of Sotalol.
SpectinomycinMesalazine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mesalazine.
SpiraprilMesalazine may decrease the antihypertensive activities of Spirapril.
SpironolactoneMesalazine may decrease the antihypertensive activities of Spironolactone.
SRT501SRT501 may increase the nephrotoxic activities of Mesalazine.
SRT501The risk or severity of adverse effects can be increased when Mesalazine is combined with SRT501.
StreptokinaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Streptokinase.
StreptomycinMesalazine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMesalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineMesalazine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleMesalazine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfasalazineMesalazine may increase the nephrotoxic activities of Sulfasalazine.
SulfisoxazoleMesalazine may increase the hypoglycemic activities of Sulfisoxazole.
SulindacSulindac may increase the nephrotoxic activities of Mesalazine.
SulindacThe risk or severity of adverse effects can be increased when Mesalazine is combined with Sulindac.
SulodexideMesalazine may increase the anticoagulant activities of Sulodexide.
SunitinibMesalazine may increase the hypoglycemic activities of Sunitinib.
SuprofenSuprofen may increase the nephrotoxic activities of Mesalazine.
SuprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Suprofen.
TacrolimusMesalazine may increase the nephrotoxic activities of Tacrolimus.
TAK-390MRThe therapeutic efficacy of Mesalazine can be decreased when used in combination with TAK-390MR.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mesalazine.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mesalazine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mesalazine.
TemocaprilMesalazine may decrease the antihypertensive activities of Temocapril.
TenecteplaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenofovir.
TenoxicamTenoxicam may increase the nephrotoxic activities of Mesalazine.
TenoxicamThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tenoxicam.
TepoxalinTepoxalin may increase the nephrotoxic activities of Mesalazine.
TepoxalinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tepoxalin.
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Mesalazine.
TeriflunomideThe risk or severity of adverse effects can be increased when Mesalazine is combined with Teriflunomide.
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Mesalazine.
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Mesalazine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tiaprofenic acid.
TicagrelorThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor.
TiclopidineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tiludronate.
TimololMesalazine may decrease the antihypertensive activities of Timolol.
TinzaparinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tinzaparin.
TioguanineThe metabolism of Tioguanine can be decreased when combined with Mesalazine.
TirofibanThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tirofiban.
TixocortolThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tixocortol.
TobramycinMesalazine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolazamideMesalazine may increase the hypoglycemic activities of Tolazamide.
TolbutamideMesalazine may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Mesalazine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tolfenamic Acid.
TolmetinTolmetin may increase the nephrotoxic activities of Mesalazine.
TolmetinThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tolmetin.
TorasemideMesalazine may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mesalazine.
TrandolaprilMesalazine may decrease the antihypertensive activities of Trandolapril.
TranilastTranilast may increase the nephrotoxic activities of Mesalazine.
TranilastThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tranilast.
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Mesalazine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mesalazine.
TriamcinoloneThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triamcinolone.
TriamtereneMesalazine may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.
TriflusalThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triflusal.
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Mesalazine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Trisalicylate-choline.
UrokinaseThe risk or severity of adverse effects can be increased when Mesalazine is combined with Urokinase.
ValdecoxibValdecoxib may increase the nephrotoxic activities of Mesalazine.
ValdecoxibThe risk or severity of adverse effects can be increased when Mesalazine is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mesalazine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mesalazine.
VorapaxarThe risk or severity of adverse effects can be increased when Mesalazine is combined with Vorapaxar.
WarfarinMesalazine may increase the anticoagulant activities of Warfarin.
XimelagatranMesalazine may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Mesalazine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zaltoprofen.
ZileutonZileuton may increase the nephrotoxic activities of Mesalazine.
ZileutonThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zoledronic acid.
ZomepiracZomepirac may increase the nephrotoxic activities of Mesalazine.
ZomepiracThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zomepirac.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690 ]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455 ]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178 ]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114 ]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965 ]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914 ]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [PubMed:15824083 ]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [PubMed:18544567 ]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications...
Gene Name:
CHUK
Uniprot ID:
O15111
Molecular Weight:
84638.88 Da
References
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [PubMed:11151876 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Molecular Weight:
86563.245 Da
References
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [PubMed:11151876 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181 ]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
nat
Uniprot ID:
P0A5L8
Molecular Weight:
Not Available
References
  1. Tucker MA, Smith TJ: Acetylation of 5-aminosalicylate by hamster colon arylamine N-acetyltransferase. J Appl Toxicol. 1990 Feb;10(1):73-4. [PubMed:2335716 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 30, 2016 02:13